GlassScriptPhysician profile
Kenneth David Glazier
NPI 1245296243
$7,119.47
in general payments reported to CMS, 2019-2025
42 companies · $1,998 in 2025
The $1,998 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $521 · 2020: $261 · 2021: $492 · 2022: $1,007 · 2023: $1,424 · 2024: $1,416 · 2025: $1,998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,784 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00 · Education: $14.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,783.57 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
| Education | $14.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,230.60 | 2021-2025 | |
| Janssen Biotech, INC. | $1,063.00 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $822.25 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $461.69 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $450.60 | 2019-2025 | |
| Ardelyx, INC. | $267.64 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $226.35 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $214.27 | 2024-2025 | Omvoh |
| Pfizer INC. | $213.96 | 2019-2025 | |
| Novo Nordisk INC | $151.77 | 2023-2025 | Wegovy |
| Allergan, INC. | $147.30 | 2019 | |
| Celgene Corporation | $145.93 | 2022-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $136.61 | 2019-2024 | Dificid |
| Genzyme Corporation | $125.00 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $106.97 | 2023-2025 | Dupixent |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $103.53 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $101.40 | 2022-2024 | Rebyota |
| Aimmune Therapeutics, INC. | $99.08 | 2024-2025 | Zenpep |
| Qol Medical, LLC | $94.74 | 2023-2024 | Sucraid, Sucraid |
| Vivus LLC | $94.52 | 2022-2025 | Qsymia, Pancreaze |
| Phathom Pharmaceuticals, INC. | $92.29 | 2024-2025 | Voquezna |
| Medtronic, INC. | $87.49 | 2024 | Endoflip |
| Boston Scientific Corporation | $82.55 | 2020 | |
| Redhill Biopharma INC. | $78.56 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $62.06 | 2019-2023 | Linzess |
| Laborie Medical Technologies Corp. | $49.49 | 2024 | Everlift |
| Daiichi Sankyo INC. | $45.17 | 2019-2023 | Injectafer |
| Intercept Pharmaceuticals, INC. | $41.30 | 2020-2023 | Ocaliva |
| Braintree Laboratories, INC. | $38.05 | 2025 | Sutab, Suflave |
| Pharmacosmos Therapeutics INC. | $33.42 | 2022-2024 | Monoferric |
| Celltrion USA INC. | $33.33 | 2024-2025 | Vegzelma |
| Intra-Sana Laboratories | $32.82 | 2023-2024 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Ipsen Biopharmaceuticals, INC | $32.68 | 2024-2025 | Iqirvo, Bylvay |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.82 | 2023 | Cyltezo |
| Amryt Pharma Holdings LTD | $19.65 | 2023 | Mycapssa |
| Cook Medical LLC | $17.79 | 2021 | |
| Sandoz INC. | $15.48 | 2025 | Hyrimoz |
| Evoke Pharma, INC. | $15.28 | 2022 | |
| Dova Pharmaceuticals | $13.87 | 2019 | |
| Concordia Pharmaceuticals INC. | $13.76 | 2019 | |
| Ucb, INC. | $13.40 | 2019 | |
| Alnylam Pharmaceuticals INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Glazier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.